Corvus Pharmaceuticals (CRVS) investor relations material

Strategic priorities and pipeline overview

• Focused on developing novel immune therapies for cancer and immune diseases, with soquelitinib as the lead program in phase III for PTCL and phase II for atopic dermatitis (AD).

• Additional phase II studies in asthma and hidradenitis suppurativa (HS) planned for the second half of the year.

• Strong IP protection for soquelitinib through 2037, with potential for five-year extensions and orphan drug exclusivity.

• Experienced management team with a track record of bringing drugs like ibrutinib and Rituxan to market.

Differentiation and clinical rationale

• Soquelitinib targets ITK, blocking both TH2 and TH17 pathways, offering potential efficacy in a broad range of immune diseases.

• Oral administration differentiates it from most current AD therapies, which are injectables; aims to improve safety and convenience over existing oral options.

• Limited tissue distribution of ITK may support a favorable safety profile.

• Demonstrated efficacy in patients who failed prior systemic therapies, suggesting potential as a first-line treatment.

Clinical data and trial design

• Phase II SIERRA-1 trial in AD is ongoing, with endpoints including EASI-75 and IGA 0/1; data readout expected in Q3 2027.

• 90-day off-treatment follow-up included to assess durability of response; positive physician feedback on durability and efficacy.

• Up to 40% of SIERRA-1 participants may have prior systemic therapy exposure, supporting broad applicability.

• Angel, the China partner, is running parallel trials with data from Cohort 1 expected by year-end.